Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 9/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.47 |
| ▸ | NPY2R | P49146 | 2/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13197589 | 0.85 | AGTR1 (0.62) | AGTR2NPY2RAGTR1 | |
| SCHEMBL13262661 | 0.83 | NPY2R (0.51) | AGTR2KLK5CTNNB1NPY2R | |
| SCHEMBL13234131 | 0.82 | AGTR1 (0.59) | AGTR2NPY2RAGTR1 | |
| SCHEMBL13234130 | 0.81 | AGTR1 (0.61) | AGTR2NPY2RAGTR1 | |
| SCHEMBL13234135 | 0.80 | AGTR1 (0.59) | AGTR2NPY2RAGTR1 | |
| SCHEMBL13232393 | 0.80 | NPY2R (0.53) | AGTR2KLK5CTNNB1NPY2RAGTR1 | |
| SCHEMBL13234138 | 0.79 | AGTR1 (0.59) | AGTR2NPY2RAGTR1 | |
| SCHEMBL13264037 | 0.79 | AGTR1 (0.56) | AGTR2NPY2RAGTR1 | |
| SCHEMBL13197592 | 0.72 | AGTR1 (0.66) | AGTR2NPY2RAGTR1 | |
| SCHEMBL18872896 | 0.72 | AGTR1 (0.68) | AGTR2NPY2RAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7785566-B2 | Pharmaceutical compounds | GE HEALTHCARE, INC. (NO) | 2010-08-31 | — | — | US | disclosed |
| US-20070134155-A1 | Pharmaceutical compounds | AMERSHAM HEALTH AS (NO) | 2007-06-14 | — | — | US | disclosed |
| US-20070134155-A1 | Pharmaceutical compounds | AMERSHAM HEALTH AS (NO) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070134155-A1 | Pharmaceutical compounds | NPPA, TNNT2, PCSK9 | AGTR2 598/4885KLK5 1090/4885CTNNB1 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.